{"id":"W2995767116","doi":"10.1016/j.jval.2019.09.2565","title":"PSS3 INDUCTION COST PER RESPONDER OF BRODALUMAB COMPARED WITH OTHER BIOLOGICS APPROVED FOR PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN CANADA","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bausch Health (Canada); Health Canada","funders":"","keywords":"Ixekizumab; Ustekinumab; Medicine; Secukinumab; Etanercept; Infliximab; Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Dermatology; Psoriatic arthritis; Internal medicine; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009603662,0.0003028966,0.001023014,0.0007239894,0.0008931137,0.001778257,0.001145431,0.0006228108,0.00481294],"category_scores_gemma":[0.004930746,0.0003674399,0.002814514,0.001995226,0.0006006929,0.0003501162,0.0004874448,0.00160353,0.000200985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.08523609,"about_ca_system_score_gemma":0.07277858,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9877232,"about_ca_topic_score_gemma":0.9894243,"domain_scores_codex":[0.9985858,0.0002931035,0.00010212,0.0001537267,0.0004415157,0.0004236655],"domain_scores_gemma":[0.9965397,0.0007012377,0.0006190438,0.00006407341,0.0009096899,0.001166194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09613223,0.001896854,0.5089896,0.0040143,0.008634464,0.001269485,0.0008468456,0.07243048,0.002935267,0.008931865,0.07385137,0.2200673],"study_design_scores_gemma":[0.01310457,0.003233152,0.9299904,0.00099959,0.005068483,0.0005585552,0.001352514,0.02962092,0.0008297477,0.0009494892,0.01410069,0.0001918659],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9479671,0.01535818,0.0003817801,0.007483586,0.0001966071,0.0003122269,0.01447671,0.0000678833,0.01375587],"genre_scores_gemma":[0.9922777,0.002738008,0.0002478806,0.000532524,0.00004310822,0.00003898572,0.002150476,0.00001378003,0.001957548],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08523609,"threshold_uncertainty_score":0.6184341,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2527293837330802,"score_gpt":0.3537193849994292,"score_spread":0.100990001266349,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}